Author

B. Gyorffy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 13 Cell Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 14 Assay:bulk RNA-seq· 10 Approach:statistical model· 10 Approach:experimental assay· 9 Research Focus:differential expression· 7 Research Focus:cancer & tumor microenvironment· 6 Research Focus:cell type annotation· 6 Research Focus:drug response / drug discovery· 4

Frequent Co-Authors

A. Bartha· 2 shared A. Mahajan· 2 shared A. Sanchez· 2 shared A. Steffen· 2 shared B. Szeitz· 2 shared C. R. A. Regenbrecht· 2 shared D. Fenyo· 2 shared D. Henderson· 2 shared

Activity by Year

2017-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Bartha

Mutual co-authors in cluster

Author profile →

16 papers

Recent·Most cited

Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts

L. Szadai, A. Bartha, I. P. Parada, A. Lakatos, D. Pal, A. S. Lengyel, N. P. d. Almeida, A. J. Janosi, F. Nogueira, B. Szeitz, V. Doma, N. Woldmar, J. Guedes, Z. Ujfaludi, Z. G. Pahi, , A. Sanchez

The paper identifies six proteins that predict response to immune checkpoint therapy across three melanoma cohorts and correlate with patient survival.

bioRxiv · May 1, 2024Cancer Biology

Identifying Ferroptosis Inducers, HDAC, and RTK Inhibitor Sensitivity in Melanoma Subtypes through Unbiased Drug Target Prediction

I. Pla, B. L. Szabolcs, P. N. Peter, Z. Ujfaludi, Y. Kim, P. Horvatovich, A. Sanchez, K. Pawlowski, E. Wieslander, J. Guedes, D. M. Pal, A. A. Ascsillan, L. H. Betancourt, I. B. Nemeth, J. Gil, , L. V. Kemeny

This paper identifies potential drug targets and predicts treatment efficacy and resistance in melanoma subtypes using proteogenomic data and drug sensitivity analysis.

bioRxiv · Feb 8, 2024 · PreprintCancer Biology

Proteomics Identifies Osteomodulin as a Promoter of Breast Cancer Bone Metastasis via CDK1 Activation

S. Cabral, J. Parsons, H. Harrison, T. Kedward, P. Fullwood, K. Spence, D. Lefley, D. Barden, J. Haworth, J. Watson, K. Tsafou, C. Behan, M. J. Dunning, N. Ali, B. Gyorffy, , R. Clarke

The paper identifies osteomodulin as a promoter of breast cancer bone metastasis through CDK1 activation using proteomics and phosphoproteomics analysis of patient-derived tumors.

bioRxiv · Nov 3, 2023 · PreprintCancer Biology

CDK19 and CDK8 Mediator kinases drive androgen-independent in vivo growth of castration-resistant prostate cancer

J. Li, T. A. Hilimire, Y. Liu, L. Wang, J. Liang, B. Gyorffy, V. Sikirzhytski, H. Ji, L. Zhang, C. Cheng, X. Ding, K. R. Kerr, C. E. Dowling, A. A. Chumanevich, G. P. Schools, , M. Chen

This study identifies CDK8 and CDK19 as drivers of androgen-independent growth in castration-resistant prostate cancer and shows that their inhibition can suppress tumor growth and induce regression.

bioRxiv · Aug 8, 2023Cancer Biology

Microenvironmental Ammonia Enhances T cell Exhaustion in Colorectal Cancer

Y. M. Shah, H. Bell, A. K. Huber, R. Singhal, R. J. Rebernick, R. Kumar, N. K. Das, S. A. Kerk, P. Sajjakulnukit, S. Solanki, J. G. James, D. Kim, L. Zhang, M. O. El-derany, T. L. Frankel, , M. Green

This study shows that ammonia accumulation in the colorectal cancer microenvironment promotes T cell exhaustion and treatment resistance, and that reducing ammonia improves immunotherapy efficacy.

bioRxiv · May 25, 2022Cancer Biology

Identification of a Nervous System Gene Expression Signature in Colon Cancer Stem Cells Reveals a Role for Neural Crest Regulators EGR2 and SOX2 in Tumorigenesis

J. L. Regan, D. Schumacher, S. Staudte, A. Steffen, R. Lesche, J. Toedling, T. Jourdan, J. Haybaeck, N. Golob-Schwarzl, D. Mumberg, D. Henderson, B. Gyorffy, C. R. A. Regenbrecht, U. Keilholz, R. Schafer, M. Lange

bioRxiv · Feb 2, 2021 · PreprintCell Biology

RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence

J. L. Regan, D. Schumacher, S. Staudte, A. Steffen, R. Lesche, J. Toedling, T. Jourdan, J. Haybaeck, D. Mumberg, D. Henderson, B. Gyorffy, C. R. A. Regenbrecht, U. Keilholz, R. Schafer, M. Lange

The paper identifies novel regulators of quiescence in colon cancer stem cells using RNA-sequencing and shows their potential as therapeutic targets.

bioRxiv · Feb 2, 2021Cell Biology

Pharmacological inhibition of the ALK axis elicits therapeutic potential in Consensus Molecular Subtype 1 colon cancer patients

M. Mazzeschi, M. Sgarzi, D. Romaniello, V. Gelfo, C. Cavallo, S. Santi, M. Fiorentino, G. D'Uva, B. Gyorffy, R. Palmer, M. Lauriola

This study shows that ALK inhibition improves outcomes in CMS1 colon cancer patients by reducing cell proliferation and enhancing cell adhesion.

bioRxiv · Oct 7, 2020 · PreprintCancer Biology

RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53

V. Jacquier, D. Gitenay, S. Fritsch, B. Gyorffy, S. Bonnet, S. Jalaguier, L. K. Linares, V. Cavailles, C. Teyssier

This study shows RIP140 inhibits breast cancer cell glycolysis and proliferation by reducing GLUT3 expression through interaction with HIF-2 and p53.

bioRxiv · Jul 30, 2020Cancer Biology

A meta-analysis of the inhibin network reveals prognostic value in multiple solid tumors

E. Listik, B. Horst, A. S. Choi, N. Lee, B. Gyorffy, K. Mythreye

This study performs a meta-analysis of the inhibin network to assess its prognostic value in multiple solid tumors, identifying key dependencies and therapeutic implications.

bioRxiv · Jun 25, 2020Cancer Biology

Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments

H. L. Palinkas, A. Bekesi, G. Rona, L. Pongor, G. Tihanyi, E. Holub, A. Poti, C. Gemma, S. Ali, M. J. Morten, E. Rothenberg, M. Pagano, D. Szuts, B. Gyorffy, B. G. Vertessy

The paper investigates genome-wide uracil distribution changes in human cells after chemotherapy, finding drug-induced shifts toward active genomic regions.

bioRxiv · Mar 4, 2020Biochemistry

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

A. I. Fernandez, X. Geng, K. Chaldekas, B. Harris, A. Duttargi, V. L. Berry, D. L. Berry, A. Mahajan, L. R. Cavalli, B. Gyorffy, M. Tan, R. B. Riggins

This study examines the association of ESRRB mRNA, copy number, and protein expression with clinicopathological features in breast cancer specimens, finding reduced ESRRB expression and distinct isoform activity in TNBC/BLBC.

bioRxiv · Aug 13, 2019Cancer Biology

Interaction between DNA damage response, translation and apoptosome determines cancer susceptibility to TOP2 poisons

C. U. Awah, L. Chen, M. Bansal, A. Mahajan, J. Winter, M. Lad, L. Warnke, E. Gonzalez-Buendia, C. Park, D. Zhang, E. Feldstein, D. Yu, M. Zannikou, I. Balyasnikova, R. Martuscello, , A. M. Sonabend

The paper identifies genes involved in DNA damage response and translation that influence susceptibility to TOP2 poisons in gliomas and other cancers.

bioRxiv · Apr 25, 2019 · PreprintCancer Biology

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

C. J. Diaz Osterman, D. Ozmadenci, E. G. Kleinschmidt, K. N. Taylor, A. M. Barrie, S. Jiang, L. M. Bean, F. J. Sulzmaier, C. Jean, I. Tancioni, K. Anderson, S. Uryu, E. A. Cordasco, J. Li, X. L. Chen, , D. D. Schlaepfer

This study identifies FAK activity as a driver of platinum resistance in ovarian cancer by sustaining CSC survival and DNA repair, showing that FAK inhibitors combined with platinum can overcome resistance.

bioRxiv · Mar 30, 2019Cancer Biology

SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer

L. Magnani, Y. Perone, A. Farrugia, A. Meira, B. Gyorffy, C. Ion, A. Uggetti, D. Patten, A. Chronopoulos, M. Faronato, S. Shousha, J. Steel, C. Davies, N. Patel, A. del Rio Hernandez, , F. Calvo

This study identifies SREBP1-driven KRT80 upregulation as a mechanism promoting invasion in endocrine-resistant ERα breast cancer through cytoskeletal changes and increased tumor stiffness.

bioRxiv · Jul 30, 2018Cancer Biology

Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

D. Patten, G. Corleone, B. Gyorffy, E. Erdos, A. Saiakhova, K. Goddard, A. Vingiani, S. Shousha, L. S. Pongor, D. Hadjiminas, G. Schiavon, P. Barry, C. Palmieri, C. Coombes, P. Scacheri, , L. Magnani

This study maps enhancers in luminal breast cancer to reveal phenotypic heterogeneity and its evolutionary dynamics during treatment.

bioRxiv · Sep 26, 2017Cancer Biology